Hospitalization risks in the treatment of schizophrenia: Comparison of antipsychotic medications

Journal of Clinical Psychopharmacology

Volumn 26, Issue 4, 2006, Pages 401-404

  Gianfrancesco, Frank ^a   Rajagopalan, Krithika ^b   Wang, Ruey Hua ^a  

^a HECON Associates Inc   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; ZIPRASIDONE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG UTILIZATION REVIEW; FEMALE; HOSPITALIZATION; HUMANS; INSURANCE COVERAGE; MALE; MEDICAID; MIDDLE AGED; REGRESSION ANALYSIS; RISK ASSESSMENT; SCHIZOPHRENIA;

EID: 33746930187     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000231536.79175.cd     Document Type: Article

References (23)

1. National Expenditures for Mental Health Services and Substance Abuse Treatment 1991-2001. US Department of Health and Human Services, Substance Abuse and Mental Health Administration. DHHS publication no. SMA 05-3999. Rockville, MD; 2005.
2. Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the "top 10" physical and mental conditions affecting 6 large U.S. employers in 1999. J Occup Environ Med. 2003;45:5-14.
3. Mauskopf JA, David K, Grainger DL, et al. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry. 1999;60(suppl 19):20-22.
4. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 2002;4:398-405.
5. Druss BG, Rosenheck RA. Patterns of health care costs associated with depression and substance abuse in a national sample. Psychiatr Serv. 1999;50:214-218.
6. Torrey EF. Surviving Schizophrenia: A Manual for Families, Consumers, and Providers. 4th ed. New York, NY: Harper Collins; 2001.
7. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997;28:199-206.
8. Mojtabai R, Lavelle J, Gibson PJ, et al. Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes. Schizophr Bull. 2003;29:519-530.
9. Csernansky JG, Schuchart EK. Relapse and rehospitalization rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs. 2002;16:473-482.
10. Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry. 1998;59(suppl):21-25.
11. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
12. Conley RR, Kelly DL, Love RC, et al. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry. 2003;15:23-31.
13. Patel NC, Dorson PG, Edwards N, et al. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv. 2002;53:891-893.
14. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenia patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry. 2001;158:266-269.
15. Brown ES, Thomas NR, Carmody T, et al. Atypical antipsychotics in bipolar and schizoaffective disorders. Pharmacopsychiatry. 2001;34:80-81.
16. Conley RR, Love RC, Kelly DL, et al. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry. 1999;156:863-868.
17. Coley KC, Carter CS, DaPos SV, et al. Effectiveness of antipsychotic therapy in a naturalistic setting. Comparison between risperidone, perphenazine and haloperidol. J Clin Psychiatry. 1999;60:850-856.
18. Buckley PF. Novel antipsychotics and patient care in state hospitals. Ann Pharmacother. 1998;32:906-914.
19. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry. 1994;55(suppl):161-165.
20. Klinkenberg WD, Calsyn RJ. Predictors of psychiatric hospitalization: a multivariate analysis. Adm Policy Ment Health. 1998;25:403-410.
21. Gianfrancesco F, Wang R, Mahmoud R, et al. Methods for claims-based pharmacoeconomic studies in psychosis. Pharmacoeconomics. 2002;20:499-511.
22. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
23. Salkever DS, Slade EP, Karakus M, et al. Estimate of antipsychotic effects of hospitalization risk in a naturalistic study with selection on unobservables. J Nerv Ment Dis. 2004;197:119-1128.